See more : iomart Group plc (IOM.L) Income Statement Analysis – Financial Results
Complete financial analysis of Phio Pharmaceuticals Corp. (PHIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phio Pharmaceuticals Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NZ Windfarms Limited (NZWFF) Income Statement Analysis – Financial Results
- Melco International Development Limited (MDEVF) Income Statement Analysis – Financial Results
- CIE Automotive India Limited (CIEINDIA.NS) Income Statement Analysis – Financial Results
- Gujarat State Petronet Limited (GSPL.BO) Income Statement Analysis – Financial Results
- Vontobel Holding AG (VONHF) Income Statement Analysis – Financial Results
Phio Pharmaceuticals Corp. (PHIO)
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 138.00K | 15.00K | 19.00K | 34.00K | 71.00K | 399.00K | 97.00K | 0.00 |
| Cost of Revenue | 6.33M | 193.00K | 192.00K | 183.00K | 4.30K | 4.33M | 5.37M | 5.42M | 6.93M | 5.68M | 17.65M | 12.98M | 0.00 |
| Gross Profit | -6.33M | -193.00K | -192.00K | -183.00K | 16.70K | -4.19M | -5.36M | -5.40M | -6.89M | -5.61M | -17.25M | -12.88M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 79.52% | -3,034.78% | -35,700.00% | -28,400.00% | -20,267.65% | -7,900.00% | -4,323.81% | -13,276.29% | 0.00% |
| Research & Development | 6.33M | 7.01M | 8.89M | 4.43M | 4.30M | 4.33M | 5.37M | 5.42M | 6.93M | 5.68M | 17.65M | 10.45M | 6.62M |
| General & Administrative | 4.29M | 4.45M | 4.63M | 4.36M | 4.71M | 3.18M | 4.01M | 3.62M | 3.35M | 3.22M | 3.70M | 2.62M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.29M | 4.45M | 4.63M | 4.36M | 4.71M | 3.18M | 4.01M | 3.62M | 3.35M | 3.22M | 3.70M | 2.62M | 6.15M |
| Other Expenses | -6.13M | -18.00K | 224.00K | -1.00K | 79.00K | 4.00K | 4.70M | 3.11M | 2.44M | 2.21M | 2.63M | 0.00 | 0.00 |
| Operating Expenses | 4.49M | 11.46M | 13.51M | 8.79M | 9.01M | 7.50M | 9.38M | 9.03M | 10.27M | 8.90M | 21.35M | 13.07M | 12.77M |
| Cost & Expenses | 10.82M | 11.46M | 13.51M | 8.79M | 9.01M | 7.50M | 9.38M | 9.03M | 10.27M | 8.90M | 21.35M | 13.07M | 12.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.00K | 30.00K | 0.00 |
| Depreciation & Amortization | 184.00K | 193.00K | 192.00K | 183.00K | 67.00K | 81.00K | 70.00K | 53.00K | 77.00K | 87.00K | 99.00K | 147.00K | 163.00K |
| EBITDA | -10.64M | -11.29M | -13.09M | -8.72M | -8.92M | -7.28M | -14.00M | -8.96M | -10.16M | -8.74M | -20.85M | -12.70M | -15.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,795.24% | -5,336.23% | -31,060.00% | -47,557.89% | -30,102.94% | -12,443.66% | -5,225.56% | -13,353.61% | 0.00% |
| Operating Income | -10.82M | -11.46M | -13.51M | -8.79M | -8.99M | -7.36M | -14.06M | -9.02M | -10.24M | -8.83M | -20.95M | -12.98M | -12.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,795.24% | -5,336.23% | -93,746.67% | -47,447.37% | -30,108.82% | -12,430.99% | -5,250.38% | -13,376.29% | 0.00% |
| Total Other Income/Expenses | -2.00K | -18.00K | 224.00K | -1.00K | 79.00K | 4.00K | -11.00K | 21.00K | 14.00K | 26.00K | 24.00K | 108.00K | 2.55M |
| Income Before Tax | -10.83M | -11.48M | -13.29M | -8.79M | -8.91M | -7.36M | -14.07M | -8.99M | -10.22M | -8.80M | -20.93M | -12.88M | -10.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,419.05% | -5,333.33% | -93,820.00% | -47,336.84% | -30,067.65% | -12,394.37% | -5,244.36% | -13,278.35% | 0.00% |
| Income Tax Expense | 0.00 | -175.00K | -75.00K | -134.30K | -67.00K | 4.00K | -1.62M | -74.00K | -91.00K | -113.00K | 0.00 | -95.00K | -2.55M |
| Net Income | -10.83M | -11.31M | -13.21M | -8.79M | -8.84M | -7.36M | -12.45M | -8.99M | -10.22M | -8.80M | -20.93M | -12.88M | -10.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,100.00% | -5,333.33% | -83,013.33% | -47,336.84% | -30,067.65% | -12,394.37% | -5,244.36% | -13,278.35% | 0.00% |
| EPS | -46.87 | -89.61 | -111.32 | -207.25 | -2.07K | -6.22K | -32.80K | -79.28K | -93.03K | -238.08K | -1.06M | -1.45M | -1.30M |
| EPS Diluted | -46.76 | -89.61 | -111.32 | -207.25 | -2.07K | -6.22K | -32.80K | -79.28K | -93.03K | -238.08K | -1.06M | -1.45M | -1.30M |
| Weighted Avg Shares Out | 231.00K | 126.16K | 118.68K | 42.43K | 4.26K | 1.18K | 379.62 | 113.44 | 109.89 | 36.96 | 19.76 | 8.88 | 7.88 |
| Weighted Avg Shares Out (Dil) | 231.51K | 126.16K | 118.68K | 42.43K | 4.26K | 1.18K | 379.62 | 113.44 | 109.89 | 36.96 | 19.76 | 8.88 | 7.88 |
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the...
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapies Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination...
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that new...
Why Is Phio Pharma (PHIO) Stock Down 35% Today?
Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterday. Investors will note that the company's stock saw a 91.2% price increase during normal trading hours on Wednesday.
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination
Phio CEO to Speak at Wainwright Conference in New York in September
He'll address clinical trial progress in Phio's lead product candidate He'll address clinical trial progress in Phio's lead product candidate
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
Trial targeting treatment of metastatic melanoma and other solid tumors Trial targeting treatment of metastatic melanoma and other solid tumors
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial...
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
Source: https://incomestatements.info
Category: Stock Reports